从大型临床试验到慢性阻塞性肺疾病的现实世界管理。

From large clinical trials to management of COPD in the real world.

作者信息

Cazzola Mario

机构信息

University of Rome 'Tor Vergata', Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy.

出版信息

Ther Adv Respir Dis. 2009 Feb;3(1):39-46. doi: 10.1177/1753465809102381.

DOI:10.1177/1753465809102381

PMID:19293202

Abstract

Large clinical trials in chronic obstructive pulmonary disease [COPD] are analyzed and discussed. Unfortunately, all of them have failed to reach their primary endpoint, which has mainly been the effect on the rate of decline in mean FEV(1) [forced expiratory volume in 1 second]. Nonetheless, almost all trials have demonstrated benefits in important outcomes such as exacerbation frequency, symptoms, quality of life and other measures of health status, which are arguably more meaningful to individual patients than FEV( 1) per se.

摘要

对慢性阻塞性肺疾病（COPD）的大型临床试验进行了分析和讨论。遗憾的是，所有这些试验均未达到其主要终点，主要终点主要是对平均第1秒用力呼气容积（FEV₁）下降率的影响。尽管如此，几乎所有试验都在诸如急性加重频率、症状、生活质量和其他健康状况指标等重要结果方面显示出益处，这些结果对个体患者而言可能比FEV₁本身更具意义。